Search

Search Results

• 

  Automated identification of cancer-associated thrombosis events via natural language processing: a systematic review of the literature

  Aidan Boyne, Emily Zhou, Ang Li

  16-04-2026

  https://doi.org/10.4081/btvb.2026.437

  486

  PDF: 129

  Appendix_Search Terms: 61
• 

  Talking about assisted reproductive techniques and thromboembolic risk: everything we always wanted to know

  Giovanni Tiscia, Elvira Grandone

  13-09-2022

  https://doi.org/10.4081/btvb.2022.43

  2660

  PDF: 437
• 

  Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy

  Dana Lee, Pedro Luiz Lage Bodour Danielian, Avi Leader

  16-04-2026

  https://doi.org/10.4081/btvb.2026.461

  290

  PDF: 151

• PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo¹, E. De Bon², L. Scarano¹, R. Fabris¹, E. Pierobon³, S. Barbar² | ¹Internal Medicine, Department of Medicine; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; ³Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.359

  806

  PDF: 6

• PO96 | Patient management with arteriovenous thrombotic manifestation and hemorrhagic complications M. Aversano, E. Cimino, L. Jr Valletta, C. Caputo, M. Romeo, M.D. Di Minno, A. Tufano, I.L. Calcaterra, C. De Luca, R. Russo, G. D’errico, P. Conca | Università degli Studi Federico II, Napoli, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.366

  567

  PDF: 3
• 

  PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm¹, N.H. Eide¹, K. Hveem^2|3|4, N. Van Es^5|6, V.M. Morelli^1|7, S.K. Braekkan^1|7, J.B. Hansen^1|7 | ¹Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; ²HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; ³HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; ⁴Department of Research, St. Olav University Hospital, Trondheim, Norway; ⁵Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; ⁶Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; ⁷Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.505

  386

  PDF: 72
• 

  PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé^1|4, F. Happe², M. Monreal^5|7, H. Robert-Ebadi⁸, P. Debourdeau⁹, J. R. Fabreguettes¹⁰, S. Accassat¹¹, P. Mismetti^4|11|12, P. Girard¹³, S. Laporte^4|12|14, C. Chapelle¹⁴ | ¹Paris Cité University; ²Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; ³Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; ⁴F-CRIN INNOVTE Network, France; ⁵Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; ⁶Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; ⁷Universidad Catolica San Antonio de Murcia, Murcia, Spain; ⁸Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; ⁹Arles Hospital, Oncology unit, Arles, France; ¹⁰Assistance Publique - Hôpitaux de Paris, AGEPS, France; ¹¹Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; ¹²Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; ¹³Département de Pneumologie, Institut Mutualiste Montsouris, Paris; ¹⁴Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.528

  355

  PDF: 80
• 

  Bleeding in cancer: epidemiological aspects

  Kelsey Bria, Amir Mahmoud, Kristen M. Sanfilippo

  16-04-2026

  https://doi.org/10.4081/btvb.2026.453

  450

  PDF: 145
• 

  Thromboprophylaxis in primary brain cancer

  Eva N. Hamulyák, Barbara A. Hutten, Nick van Es

  16-04-2026

  https://doi.org/10.4081/btvb.2026.455

  275

  PDF: 128

• PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo¹, E. De Bon², L. Scarano¹, R. Fabris¹, E. Pierobon³, S. Barbar² | ¹Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; ³Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.339

  597

  PDF: 10
• 

  PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati^1|2, P. Gomez-Rosas^1|3, C. Ambaglio¹, V. Brusegan¹, O.C. Cretu¹, E. Galimberti¹, F. Zunino¹, L. Barcella¹, J. Harenberg^4|5, A. Falanga^1|2, M. Marchetti^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ⁴Ruprecht Karls University of Heidelberg, Heidelberg, Germany; ⁵DOASENSE GmbH, Heidelberg, Germany

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.522

  337

  PDF: 86

• PO51 | Thrombocythemia associated with a non-canonical JAK2 mutation: a case report G. Rosati, A. Pozzi, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.320

  715

  PDF: 4

• PO25 | Baseline thrombin generation test does not predict thrombotic events in acute leukemia: a monocentric prospective study M. Biglietto, R. Mormile, M.L. Bisegna, A. Laganà, A. L. Faccini, A. Papa, E. Baldacci, C. Santoro, M.S. De Propris, A. Chistolini | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.286

  616

  PDF: 3

• PO64 | A silent hemorrhage in the immuno-thrombotic chaos of antiphospholipid syndrome G. Autiero, S.A. Malerba, A. Malaguti, M. Dalla Vestra, F. Presotto | Medicina Generale, Ospedale dell’Angelo, Mestre-Venezia, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.333

  624

  PDF: 8

• CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas^1,2, M. Marchetti^1,3, L. Russo¹, C.J. Tartari¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁵, A. Falanga^1,3 All on behalf of the Hypercan Investigators | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; ³School of Medicine and Surgery, University of Milan Bicocca, Italy; ⁴University Vita-Salute San Raffaele, Milan, Italy; ⁵Fondazione ARTET Onlus, Bergamo, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.220

  603

  PDF: 4

• PO47 | Hemophilia A and antithrombin deficiency: a case of natural hemostatic rebalancing L. Torrieri, S. Ligia, E. Baldacci, R. Mormile, S. Sorella, R. Ciciani, M. Biglietto, N. Zhdanovskaya, A. Delli Paoli, A. Tirnetta, M. Lorenzon, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.316

  594

  PDF: 5
• 

  Anticoagulation during anti-angiogenic cancer therapy: balancing risks of thrombosis and bleeding

  Nikola Vladic, Florian Moik

  16-04-2026

  https://doi.org/10.4081/btvb.2026.452

  253

  PDF: 132
• 

  PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva¹, V. Bitsadze¹, A. Vorobev¹, A. Solopova¹, M. Tretyakova¹, N. Gashimova¹, K. Grigoreva¹, A. Khisamieva¹, J. Gris^1|2, I. Elalamy^1|3|4, G. Gerotziafas^1|3|4, A. Makatsariya¹ | ¹Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; ²Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; ³Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; ⁴Hospital Tenon, Paris, France

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.517

  347

  PDF: 79

• PO61 | ACTN1-related thrombocytopenia and severe hyperhomocysteinemia: a case report A. Pozzi, G. Rosati, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, San Luigi Hospital, Orbassano (TO), Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.330

  538

  PDF: 4
• 

  PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY D. Siegal^1|2, Z. O’Neill^1|2, L. Nguyen³, N. Liu³, M. Carrier^1|2, R. Sutradhar^3|4 | ¹Ottawa Hospital Research Institute, Ottawa; ²Department of Medicine, University of Ottawa, Ottawa; ³ICES, Toronto, Canada; ⁴Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

  ICTHIC 2026

  16-04-2026

  https://doi.org/10.4081/btvb.2026.510

  398

  PDF: 85

• PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella^1,2, V. Coluccio³, M. Luppi¹, M. Marietta¹ |  ¹Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; ²Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; ³Department of Hematology, Unità Sanitaria Locale di Modena, Italy 

  22-10-2025

  https://doi.org/10.4081/btvb.2025.270

  540

  PDF: 7